Last reviewed · How we verify
YTTRIUM Y 90 EPRATUZUMAB
YTTRIUM Y 90 EPRATUZUMAB is a drug. It is currently in Phase 1 development.
At a glance
| Generic name | YTTRIUM Y 90 EPRATUZUMAB |
|---|---|
| Modality | Monoclonal antibody |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG (PHASE1, PHASE2)
- Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL (PHASE1, PHASE2)
- Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma (PHASE1)
- Safety Study of NHL With 90Y-hLL2 IgG (PHASE1, PHASE2)
- Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma (PHASE1, PHASE2)
- Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL (PHASE2)
- Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia (PHASE1, PHASE2)
- Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+ (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YTTRIUM Y 90 EPRATUZUMAB CI brief — competitive landscape report
- YTTRIUM Y 90 EPRATUZUMAB updates RSS · CI watch RSS
Frequently asked questions about YTTRIUM Y 90 EPRATUZUMAB
What is YTTRIUM Y 90 EPRATUZUMAB?
YTTRIUM Y 90 EPRATUZUMAB is a Monoclonal antibody drug.
What development phase is YTTRIUM Y 90 EPRATUZUMAB in?
YTTRIUM Y 90 EPRATUZUMAB is in Phase 1.